Value
4.3/10data confidence 83%| Component | Sub-score |
|---|---|
| P/E | 0.0 |
| P/S | 4.7 |
| Fwd P/E | 2.1 |
| PEG | 9.6 |
| Analyst target | 5.0 |
- ▸Forward P/E: 55.1x
- ▸PEG: 0.56
VCEL · Why this verdict
Why Vericel (VCEL) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score5.8/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Vericel has beaten earnings estimates in all four of the most recent quarters with an average upside surprise of 241%, demonstrating that management is consistently setting conservative guidance and then outperforming, which tends to attract institutional momentum buyers. Earnings | Vericel beats consensus earnings estimates in at least 3 of the next 4 quarters, maintaining the positive surprise trend. | →Stable |
| CounterThe average surprise figure is skewed by one outsized quarter with an 850% beat; stripping that out, the remaining beats are more modest, suggesting the streak may reflect guidance conservatism rather than durable structural outperformance. | ||
Vericel passes the Rule of 40 with a score of 45, combining 30% revenue growth with improving profitability, placing it in the minority of small-cap healthcare companies that balance expansion speed with capital efficiency. Quality breakdown | Revenue growth remains above 20% year-over-year and the Rule of 40 score stays above 35 over the next four quarters. | →Stable |
| CounterThe company's return on equity is only 2.2% and return on assets is 1.4%, indicating the growth is not yet translating into meaningful capital returns, and a slowdown in procedure volumes from its key tissue-repair products could quickly push the Rule of 40 score below threshold. | ||
Vericel's reliance on two sole-source suppliers, Matricel GmbH and MediWound, for critical raw materials creates a supply chain vulnerability that could halt product manufacturing if either supplier experiences regulatory, financial, or capacity issues. Bear case | No supply disruption events are announced and both supplier relationships are described as intact in the next annual filing, with no production delays affecting revenue. | →Stable |
| CounterSole-source supplier arrangements in regulated medical manufacturing are common and typically managed through long-term contracts and safety stock; the risk may be lower in practice than the disclosure language implies. | ||
Analysts have set a consensus price target implying 45% upside from the current price of $38.29, and the stock trades with a favorable reward-to-risk ratio of 3.7x, suggesting the market has not yet fully recognized the company's growth trajectory. Targets | The stock price rises above $45 within 12 months, closing more than 50% of the gap to the analyst consensus target of approximately $48. | →Stable |
| CounterWith a small market cap below $5 billion and high implied volatility of 110%, the analyst target may incorporate significant optimism about future pipeline approvals that have not yet materialized; the target could be revised downward if near-term catalysts disappoint. | ||
Vericel has beaten earnings estimates in all four of the most recent quarters with an average upside surprise of 241%, demonstrating that management is consistently setting conservative guidance and then outperforming, which tends to attract institutional momentum buyers.
→StableEarnings
- Expectation
- Vericel beats consensus earnings estimates in at least 3 of the next 4 quarters, maintaining the positive surprise trend.
CounterThe average surprise figure is skewed by one outsized quarter with an 850% beat; stripping that out, the remaining beats are more modest, suggesting the streak may reflect guidance conservatism rather than durable structural outperformance.
Vericel passes the Rule of 40 with a score of 45, combining 30% revenue growth with improving profitability, placing it in the minority of small-cap healthcare companies that balance expansion speed with capital efficiency.
→StableQuality breakdown
- Expectation
- Revenue growth remains above 20% year-over-year and the Rule of 40 score stays above 35 over the next four quarters.
CounterThe company's return on equity is only 2.2% and return on assets is 1.4%, indicating the growth is not yet translating into meaningful capital returns, and a slowdown in procedure volumes from its key tissue-repair products could quickly push the Rule of 40 score below threshold.
Vericel's reliance on two sole-source suppliers, Matricel GmbH and MediWound, for critical raw materials creates a supply chain vulnerability that could halt product manufacturing if either supplier experiences regulatory, financial, or capacity issues.
→StableBear case
- Expectation
- No supply disruption events are announced and both supplier relationships are described as intact in the next annual filing, with no production delays affecting revenue.
CounterSole-source supplier arrangements in regulated medical manufacturing are common and typically managed through long-term contracts and safety stock; the risk may be lower in practice than the disclosure language implies.
Analysts have set a consensus price target implying 45% upside from the current price of $38.29, and the stock trades with a favorable reward-to-risk ratio of 3.7x, suggesting the market has not yet fully recognized the company's growth trajectory.
→StableTargets
- Expectation
- The stock price rises above $45 within 12 months, closing more than 50% of the gap to the analyst consensus target of approximately $48.
CounterWith a small market cap below $5 billion and high implied volatility of 110%, the analyst target may incorporate significant optimism about future pipeline approvals that have not yet materialized; the target could be revised downward if near-term catalysts disappoint.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Vericel Corporation has delivered four consecutive quarterly earnings beats with 30% year-over-year revenue growth and a Rule of 40 score of 45, positioning it as a high-growth regenerative medicine company, though a 13% short interest and 110% implied volatility signal elevated speculative risk.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 2.2 |
| ROA | 1.4 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 3.7 |
| Current ratio | 7.8 |
| FCF quality | 10.0 |
| Moat | 7.9 |
| Rule of 40 | 7.6 |
| Piotroski F | 10.0 |
- ▸Excellent cash conversion: 197% FCF/NI
- ▸Wide economic moat
- ▸Rule of 40: 45 (pass)
- ▸Strong Piotroski F-Score: 9/9
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 30% YoY
Momentum
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.0 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 2.5 |
- ▸Overbought (RSI 79)
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 7.5 |
| erm sentiment | 5.0 |
Insider
3.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.2 |
- ▸Modest insider selling — $1,715,875 (0.072% of mkt cap)
Peer rank
4.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.1 |
| quality rank | 6.9 |
| growth rank | 6.0 |
- ▸Superior ROE vs peers
Technical
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.4 |
| support resistance | 0.1 |
| 52w position | 10.0 |
Risk (lower is worse)
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.3 |
| days to cover | 0.6 |
| volatility | 3.2 |
| put call | 10.0 |
| implied vol | 2.3 |
| beta | 6.7 |
| debt equity | 8.9 |
- ▸High IV: 66%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (7)
- MOMENTUM:5.3>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:27d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.2<1.5@spot
Warning (1)
- MOMENTUM:5.3<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
0.18
Upside
+2.6%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeCatalyst-Driven — Earnings in 27d with 4/4 beat streak
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:5.3>=4.5. Top dim: Growth at 10.0; weakest: Technical at 3.5. No conviction either direction.
The strongest dimensions are Growth at 10.0, Catalyst at 7.5, and Quality at 6.1; the weakest are Technical at 3.5, Insider at 3.9, and Peer rank at 4.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 0.18 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Consecutive Earnings Beat Streak
Trip ifEarnings per share surprise falls below 0% in at least 2 of the next 4 quarters, breaking the beat streak.
- P2Rule Of 40 Growth Quality
Trip ifRevenue growth falls below 15% year-over-year for 2 consecutive quarters, dropping the Rule of 40 score below 30.
- P3Supplier Concentration Pipeline Risk
Trip ifProduction delay of more than 30 days is announced due to a supplier issue, causing revenue guidance to decrease by more than 5%.
- P4Analyst Upside Target Gap
Trip ifStock price drops below $32, more than 16% below the current $38.29, on a negative catalyst such as a clinical setback or earnings miss.